As the CEO of CellArtgen, the company that professor Seung-Woo Cho founded for the translation of our lab's research into clinical applications, our principal investigator had an interview with Dong-A Science.

Recently, using organoids in regenerative therapies was approved in South Korea. With its exclusive technologies, decellularized tissue matrices and microfluidic fluid control systems, CellArtgen, in collaboration with SCEBL, is at the forefront of the field, producing advanced organoids. It has developed various disease models, and has launched organoids-based drug screening services.

Please follow the link below for more details

[Link]